Results 101 to 110 of about 5,673,125 (350)

Adjuvant chemotherapy for rectal cancer with complete pathological response (pCR) may not be necessary: a pooled analysis of 5491 patients

Cancer Cell International, 2019
Background It is recommended postoperative adjuvant chemotherapy for all rectal cancers undergoing neo-chemoradiotherapy regardless of the final yield pathology.
Xiang Hu, Ya-Qi Li, Xiao-ji Ma, Long Zhang, San-Jun Cai, Jun-Jie Peng   +5 more
doaj   +1 more source

Clinicopathological determinants of an elevated systemic inflammatory response following elective potentially curative resection for colorectal cancer [PDF]

, 2017
Introduction: The postoperative systemic inflammatory response (SIR) is related to both long- and short-term outcomes following surgery for colorectal cancer.
Horgan, Paul G., McMillan, Donald C., McSorley, Stephen T., Park, James H., Ramanathan, Michelle L., Walley, Killian, Watt, David G.   +6 more
core   +2 more sources

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Identification of PANoptosis associated lncRNAs associated with clinical prognosis and immune infiltration microenvironment in colon adenocarcinoma

Discover Oncology
Early diagnosis and disease management based on risk stratification have a very positive impact on colon adenocarcinoma (COAD) prognosis. It is of positive significance to further explore risk stratification of COAD patients and identify predictive ...
Yangyang Wang, Shihui Zhao, Songtao Du, Tianyi Xia, Liqiang Song, Mingyu Xia, Bomiao Zhang   +6 more
doaj   +1 more source

MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. [PDF]

, 2012
BackgroundUpregulation of the matrix metalloproteinases MMP-2 and MMP-9 in various cancers has been associated with worse survival of the patients.MethodsWe assessed MMP-2 and MMP-9 levels in normal colorectal mucosa from colorectal cancer patients in ...
Hardwick, JCH, Hawinkels, LJAC, Hommes, DW, Kubben, FJGM, Langers, AMJ, Sier, CFM, van der Reijden, JJ, van Duijn, W, Verspaget, HW   +8 more
core   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. [PDF]

, 2020
PurposeThe goal of the present study was to determine the efficacy of temozolomide (TEM) and pazopanib (PAZ) combined with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) on a colorectal cancer patient-derived orthotopic xenograft (PDOX) mouse model ...
Bouvet, Michael, Clary, Bryan, Han, Qinghong, Hoffman, Robert M, Singh, Shree Ram, Sun, Yu, Tan, Yuying, Ye, Jianxin, Zhao, Ming, Zhu, Guangwei   +9 more
core  

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source